Navigation Links
Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
Date:12/11/2011

p>Dr. Meyer will present this study in an oral presentation on Monday, December 12, at 3:00 p.m. PST at the San Diego Convention Center in Ballroom 20A.

Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study [Abstract 269]

The first clinical trial to directly compare rituximab with the new anti-CD20 monoclonal antibody obinutuzumab for the treatment of relapsed non-Hodgkin lymphoma (NHL) has shown higher response rates for patients treated with the novel therapy.

NHL survival rates have increased dramatically in the last several decades because of such proven and effective targeted therapies as rituximab that aim directly at the key molecular features of the disease. Despite advances in NHL treatment, hematologists continue to be challenged by drug resistance and disease relapses among their patients. Obinutuzumab, also known as GA101, is a new investigational therapy and the first type II bio-engineered monoclonal antibody specifically targeting CD20 (a prominent lymphoma biomarker) to be studied for use in NHL. Early research with GA101 has shown potential anti-lymphoma activity, but no studies have compared the results against current clinical options directly.

To compare the efficacy and safety of GA101 versus rituximab in patients with relapsed NHL, an international Phase II clinical trial was undertaken measuring overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety outcomes among patients on both treatments. A total of 175 patients were randomized to receive four weekly injections of either GA101 or rituximab with response to treatment assessed between 28 and 42 days after the last dose. Those patients who responded to treatment received ongoing doses of GA101 or rituximab every t
'/>"/>

SOURCE American Society of Hematology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Established and Emerging Biotech Clusters
2. PAREXEL International to Present at Robert Baird Healthcare Conference and William Blair Emerging Growth Stock Conference
3. Tumor Marker Diagnostic Technologies: Assessment of Current and Emerging Technologies, And Their Potential Market Applications
4. GRAPHENE-CA appointed an EU Future Emerging Technology flagship pilot
5. Reportlinker Adds Top & Emerging Bio-Fuel Markets by Technology, Feedstocks, Regulations, Pricing & Commercialization Trends & Forecasts (2011 - 2016)
6. Reportlinker Adds The 2011 Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers
7. Zimmer Helps Physicians and Hospitals Negotiate Emerging Health Care Business Challenges Through New Consulting Programs
8. Elixir Bio-Tech Inc. Elected One of Top 50 Emerging Companies by 100 Venture Capital Funds & Angel Investors
9. Reportlinker Adds Future US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends Through 2018
10. Reportlinker Adds The 2011 Coagulation Testing Market: US, Europe, Japan Emerging Business Opportunities and Market Expansion Strategies for Suppliers
11. Reportlinker Adds Emerging Opportunities in Biosimilar and Biobetter Drugs Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... U.S. Securities and Exchange Commission. The filed Form 20-F ... March 31, 2015. The Form 20-F can be accessed ...
(Date:7/30/2015)... , July 30, 2015   GenoSpace , ... the interpretation and analysis of genomic and other ... has joined the company as Vice President ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners ... integrate, interpret, analyze and explore complex sets of ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative veterinary medicine company, ... canine osteoarthritis stem cell product, currently under development for FDA approval. The product ... marketed in the US by Aratana. This product, termed AT-016, is an allogeneic ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... is making,progress in the development of sustainable biofuels. The recent first crop of,genetically modified poplars of the Flemish Institute for Biotechnology (VIB),will be modified into bioethanol in a Flemish-Dutch pilot ... , ... ... ...
... He is joined by scientists scattered from Ann Arbor to Osaka on the annual Thomson Reuters list of the world,s 12 hottest researchers. , ... , ... ... ...
... ... Kimberly Thompson wins $5,000 in CUNY Nobel Science Challenge. , ... New York, NY (Vocus) March 12, 2010 -- Borough ... the economics category of the 2009 CUNY Nobel Science Challenge—as well as $5,000 as an ...
Cached Biology Technology:Bio Base Europe: Flanders and the Netherlands Cooperate on Biofuels From Genetically Modified Poplars 2Bio Base Europe: Flanders and the Netherlands Cooperate on Biofuels From Genetically Modified Poplars 3Thomson Reuters Names the World's 'Hottest' Researchers 2Thomson Reuters Names the World's 'Hottest' Researchers 3Thomson Reuters Names the World's 'Hottest' Researchers 4Thomson Reuters Names the World's 'Hottest' Researchers 5BMCC Student—the Only Community College Winner—Lands Grand Prize in Nobel Science Challenge 2
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
(Date:7/23/2015)... 23, 2015 Aware, Inc. (NASDAQ: AWRE ), ... financial results for its second quarter ended June 30, 2015.  ... was $4.5 million, a decrease of 33% compared to $6.8 ... the second quarter of 2015 was $0.3 million, or $0.01 ... per diluted share, in the same period a year ago.  ...
(Date:7/20/2015)... , July 20, 2015  Acuity Market Intelligence,s ... The Convergence of Commerce and Privacy" forecasts that ... biometric apps will be downloaded to smart mobile ... mobile biometrics market is projected to generate more ... during the seven-year forecast period.    ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... children were born in public clinics in Denmark, projecting a net ... 50 years respectively. The authors of the study calculated that reductions ... to cost savings of 67 - 111 million for the Danish ... 50 years of age, the government would have lost 74 - ...
... 6, 2011 A first-of-its-kind study of a patient with lung ... the Virginia G. Piper Cancer Center at Scottsdale Healthcare at the ... Researchers for the first time sequenced the entire DNA and RNA ... Glen Weiss, the first author of the study, which will be ...
... bird, the statuesque whooping crane ( Grus americana ), is ... Smithsonian,s National Zoological Park. An 11-year-old male whooping crane named ... now on exhibit in the nation,s capital. Whooping cranes are ... States. There are only eight other zoos in the U.S. ...
Cached Biology News:The long-term fiscal impact of funding cuts for IVF in Denmark 2First whole-genome lung cancer study by TGen and Virginia G. Piper Cancer Center set for conference 2National Zoo Welcomes Whooping Crane 2
... APAgene kits are designed to rapidly ... using our patented APA Technology. ... at an extraordinarily competitive price. All ... kit. The Locator Kit can be ...
... one of the several main MAP kinase ... a sensitive reporter for studying gene regulation ... in sensitivity in comparison to the standard ... the oxidative carboxylation of luciferin, a reaction ...
Recommended for supporting the growth of anchorage-dependent cells including human and mouse stromal cells, mesenchymal cells and cell lines....
... FailSafe™ PCR System is the only PCR ... time and every time. It provides accuracy, ... the source or the property of the ... PCR Enzyme Mix, a unique blend of ...
Biology Products: